ABSTRACT
No disponible
Subject(s)
Humans , Hypertension, Pulmonary/therapy , Exercise Therapy/methods , Exercise Movement TechniquesABSTRACT
Desde 2009, el tadalafilo, un potente y selectivo inhibidor de la fosfodiesterasa tipo 5 (PDE5), puede representar una nueva alternativa terapéutica eficaz y segura para pacientes con hipertensión pulmonar (HP) en clases funcionales II y III de la Organización Mundial de la Salud (OMS) como detallan las «Guías de práctica clínica para el diagnóstico y tratamiento de la HP» de la Sociedad Europea de Cardiología (ESC) y de la European Respiratory Society (ERS), en términos de beneficios en ejercicio, en retraso del deterioro clínico y en calidad de vida. Por otra parte, dado su mayor vida media, que permite su dosificación única diaria oral de 40 mg, podría mejorar el cumplimiento terapéutico facilitando una mayor adhesión al tratamiento de los pacientes con HP (AU)
Tadalafil, which was commercialized in 2009, is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, and may be a safe and effective therapeutic alternative for patients with class II and III pulmonary hypertension (PH) in the World Health Organizations classification as stated in the Clinical Practice Guidelines for the Diagnosis and Treatment of PH of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) providing benefits in exercise tolerance, delaying clinical deterioration and improving quality of life. Given the greater half-life of this drug, allowing a single oral dose of 40 mg per day, tadalafil could improve therapeutic compliance thus facilitating treatment adherence among patients with PH (AU)
Subject(s)
Humans , Carbolines/adverse effects , Carbolines/pharmacology , Carbolines/therapeutic use , Hypertension, Pulmonary/drug therapy , Hypertension, Pulmonary/enzymology , Phosphodiesterase 5 Inhibitors/adverse effects , Phosphodiesterase 5 Inhibitors/pharmacology , Phosphodiesterase 5 Inhibitors/therapeutic use , Second Messenger Systems , Cyclic GMP/metabolism , Cyclic Nucleotide Phosphodiesterases, Type 5/physiology , Double-Blind Method , Drug Interactions , Exercise Tolerance , Molecular Structure , Prognosis , Quality of Life , Randomized Controlled Trials as TopicABSTRACT
Tadalafil, which was commercialized in 2009, is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, and may be a safe and effective therapeutic alternative for patients with class II and III pulmonary hypertension (PH) in the World Health Organization's classification--as stated in the Clinical Practice Guidelines for the Diagnosis and Treatment of PH of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)--providing benefits in exercise tolerance, delaying clinical deterioration and improving quality of life. Given the greater half-life of this drug, allowing a single oral dose of 40 mg per day, tadalafil could improve therapeutic compliance--thus facilitating treatment adherence--among patients with PH.
